Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 24 new employees, totaling 20,334 shares of company common stock. The grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for April 1, 2025.
The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting annually, contingent upon continued employment.
Incyte (INCY) ha annunciato l'assegnazione di premi in azioni vincolate (RSU) a 24 nuovi dipendenti, per un totale di 20.334 azioni ordinarie della società. I premi sono stati concessi nell'ambito del Piano di Incentivazione Azionaria per Induzione 2024, con la data di concessione e l'inizio del periodo di maturazione fissati per il 1 aprile 2025.
I premi sono stati approvati dal comitato per la compensazione del consiglio di amministrazione di Incyte come incentivo per i nuovi dipendenti che si uniscono all'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Le RSU matureranno in quattro anni, con il 25% delle azioni che maturerà annualmente, a condizione di continuare l'impiego.
Incyte (INCY) ha anunciado la concesión de premios en acciones restringidas (RSU) a 24 nuevos empleados, totalizando 20,334 acciones ordinarias de la empresa. Las concesiones se realizaron bajo el Plan de Incentivos de Acciones por Inducción 2024, con la fecha de concesión y la fecha de inicio de adquisición establecidas para el 1 de abril de 2025.
Los premios fueron aprobados por el comité de compensación de la junta directiva de Incyte como un incentivo para los nuevos empleados que se unen a la empresa, en cumplimiento con la Regla de Cotización de Nasdaq 5635(c)(4). Las RSU se adquirirán durante cuatro años, con el 25% de las acciones adquiriéndose anualmente, sujeto a la continuación del empleo.
인사이트 (INCY)는 24명의 신규 직원에게 총 20,334주의 회사 보통주에 대한 제한된 주식 단위 보상(RSU)을 부여한다고 발표했습니다. 이 보상은 2024 유도 주식 인센티브 계획에 따라 이루어졌으며, 부여일과 권리 발생 시작일은 2025년 4월 1일로 설정되었습니다.
이 보상은 인사이트 이사회 보상위원회에 의해 승인되었으며, 신규 직원들이 회사에 합류하는 유인책으로 제공되며, 나스닥 상장 규칙 5635(c)(4)를 준수합니다. RSU는 4년에 걸쳐 권리 발생되며, 매년 25%의 주식이 권리 발생되며, 계속 고용되는 조건입니다.
Incyte (INCY) a annoncé l'octroi de récompenses en unités d'actions restreintes (RSU) à 24 nouveaux employés, totalisant 20 334 actions ordinaires de la société. Les octrois ont été réalisés dans le cadre du Plan d'Incitation à l'Action pour Induction 2024, avec la date d'octroi et la date de début de l'acquisition fixées au 1er avril 2025.
Les récompenses ont été approuvées par le comité de rémunération du conseil d'administration d'Incyte comme une incitation pour les nouveaux employés rejoignant l'entreprise, conformément à la règle d'inscription Nasdaq 5635(c)(4). Les RSU seront acquises sur une période de quatre ans, avec 25 % des actions acquises annuellement, sous réserve de la continuité de l'emploi.
Incyte (INCY) hat die Gewährung von Restricted Stock Units (RSUs) an 24 neue Mitarbeiter angekündigt, insgesamt 20.334 Aktien des Unternehmens. Die Gewährungen erfolgten im Rahmen des 2024 Inducement Stock Incentive Plans, wobei sowohl das Gewährungsdatum als auch das Datum des Beginns der Vesting am 1. April 2025 festgelegt wurden.
Die Auszeichnungen wurden vom Vergütungsausschuss des Vorstands von Incyte genehmigt, um neue Mitarbeiter zu motivieren, die dem Unternehmen beitreten, und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs werden über einen Zeitraum von vier Jahren fällig, wobei 25% der Aktien jährlich fällig werden, vorausgesetzt, dass das Arbeitsverhältnis fortgesetzt wird.
- Employee retention strategy through four-year vesting schedule
- Successful talent acquisition with 24 new hires
- Potential dilution of existing shareholders through 20,334 new shares
Each RSU vests as to
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407810295/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte
FAQ
How many shares of RSUs did Incyte (INCY) grant to new employees in April 2025?
What is the vesting schedule for Incyte's (INCY) April 2025 RSU grants?
Under which plan were Incyte's (INCY) April 2025 RSU grants made?
How many new employees received RSU grants from Incyte (INCY) in April 2025?
